2026-06-14T03:18:06Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/198812025-03-24T08:42:57Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16978

00925njm 22002777a 4500 dc Muñoz-Gómez, María José author Ryan, Pablo author Quero-Delgado, Marta author Martin-Vicente, Maria author Cuevas, Guillermo author Valencia, Jorge author Jiménez, Eva author Blanca-López, Natalia author Lara-Álvarez, Miguel Ángel author Hernández-Rivas, José Ángel author Redondo, Gerardo author Mas-Lloret, Vicente author Sepulveda-Crespo, Daniel author Vazquez-Alcaraz, Monica author Torres-Macho, Juan author Martinez, Isidoro author Resino, Salvador author 2024-07 Background: Cancer patients often have weakened immune systems, resulting in a lower response to vaccines, especially those receiving immunosuppressive oncological treatment (OT). We aimed to assess the impact of OT on the humoral and T-cell response to the B.1 lineage and Omicron variant following COVID-19 vaccination in patients with solid and hematological neoplasms. Methods: We conducted a prospective study on cancer patients, stratified into OT and non-OT groups, who received a two-dose series of the COVID-19 mRNA vaccine and a booster six months later. The outcomes measured were the humoral (anti-SARS-CoV-2 S IgG titers and ACE2-S interaction inhibition capacity) and cellular (SARS-CoV-2 S-specific T-cell spots per million PBMCs) responses against the B.1 lineage and Omicron variant. These responses were evaluated four weeks after the second dose (n = 98) and eight weeks after the booster dose (n = 71). Results: The humoral response after the second vaccine dose against the B.1 lineage and Omicron variant was significantly weaker in the OT group compared to the non-OT group (q-value<0.05). A booster dose of the mRNA-1273 vaccine significantly improved the humoral response in the OT group, making it comparable to the non-OT group. The mRNA-1273 vaccine, designed for the original Wuhan strain, elicited a weaker humoral response against the Omicron variant compared to the B.1 lineage, regardless of oncological treatment or vaccine dose. In contrast, T-cell responses against SARS-CoV-2, including the Omicron variant, were already present after the second vaccine dose and were not significantly affected by oncological treatments. Conclusions: Cancer patients, particularly those receiving immunosuppressive oncological treatments, should require booster doses and adapted COVID-19 vaccines for new SARS-CoV-2 variants like Omicron. Future studies should evaluate the durability of the immune response and the efficacy of individualized regimens. J Infect Public Health. 2024 Jul;17(7):102473. 10.1016/j.jiph.2024.102473 1876-035X Journal of infection and public health 38865774 http://hdl.handle.net/20.500.12105/19881 SARS-CoV-2 COVID-19 vaccine Immune responses B.1 lineage Omicron variant Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study